Austin, Texas, United States, March 6th, 2026, FinanceWire
- Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages.
- Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action.
- HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis.
Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix (NASDAQ: SNGX) exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact.
Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. In drug development, platform technology is a foundational technology or system that serves as a base for the development of multiple products, solutions or…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Contact
IBN
512.354.7000 Office
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
